nach oben

Journal of Endocrinological Investigation

Erschienen in:

01.08.2019 | Short Review

Local ablative therapy of oligoprogressive TKI-treated thyroid cancer

verfasst von: T. Porcelli, F. Sessa, C. Luongo, D. Salvatore

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Abstract

Metastatic cancer patients generally respond well to treatment with tyrosine kinase inhibitors (TKIs). However, TKI resistance occurs in almost all cases and often leads to a change in treatment. Recent guidelines, including thyroid cancer, raised the possibility of locally treating TKI-resistant oligoprogressive disease, i.e., one or a few progressing lesions in an otherwise treatment-responsive metastatic cancer, thereby obviating the need to change the ongoing TKI. To determine the benefits of this intervention, we reviewed studies on the use of LAT for TKI-treated oligoprogressive cancers. We found that in non-small cell lung cancer at least, LAT prolongs disease control and the duration of exposure to a TKI irrespective of the LAT used. Moreover, we reviewed the local ablative therapies (LATs) that are feasible for the local control of oligoprogressive thyroid cancer. Lastly, we report two illustrative cases of patients with oligoprogressive thyroid cancer treated with two different LATs while on therapy with TKIs. Both LATs extended the duration of disease control and the time of exposure to the ongoing TKI, thereby indicating that LAT is a favorable option for TKI-treated oligoprogressive thyroid cancer. Prospective randomized studies are needed to verify the benefit of LATs in terms of progression-free and overall survival in this increasingly frequent clinical setting.

Droz JP, Schlumberger M, Rougier P et al (1990) Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori 76(5):480–483CrossRefPubMed

Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346(2):92–98. https://doi.org/10.1056/NEJMoa011954 CrossRefPubMed

Schmid TA, Gore ME (2016) Sunitinib in the treatment of metastatic renal cell carcinoma. Ther Adv Urol 8(6):348–371. https://doi.org/10.1177/1756287216663979 CrossRefPubMedPubMedCentral

Sapuppo G, Tavarelli M, Russo M et al (2018) Lymph node location is a risk factor for papillary thyroid cancer-related death. J Endocrinol Invest 41(11):1349–1353. https://doi.org/10.1007/s40618-018-0865-5 CrossRefPubMed

Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26(1):1–133. https://doi.org/10.1089/thy.2015.0020 CrossRefPubMedPubMedCentral

Hanna N, Johnson D, Temin S et al (2017) Systemic therapy for stage iv non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 35(30):3484–3515. https://doi.org/10.1200/JCO.2017.74.6065 CrossRefPubMed

Escudier B, Potra C, Schmidinger M et al (2016) Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(suppl 5):58–68. https://doi.org/10.1093/annonc/mdw328 CrossRef

Novello S, Barlesi F, Califano R et al (2016) Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(suppl 5):1–27. https://doi.org/10.1093/annonc/mdw326 CrossRef

Winkler GC, Lovsin Barle E, Galati G et al (2014) Functional differentiation of cytotoxic cancer drugs and targeted cancer therapeutics. Regul Toxicol Pharmacol 70(1):46–53. https://doi.org/10.1016/j.yrtph.2014.06.012 CrossRefPubMed

10.

Camidge DR, Pao W, Sequist LV (2014) Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol 11(8):473–481. https://doi.org/10.1038/nrclinonc.2014.104 CrossRefPubMed

11.

Westover D, Zugazagoitia J, Cho BC et al (2018) Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol 29(suppl 1):10–19. https://doi.org/10.1093/annonc/mdx703 CrossRef

12.

Lin JJ, Shaw AT (2016) Resisting resistance: targeted therapies in lung cancer. Trends Cancer 2(7):350–364. https://doi.org/10.1016/j.trecan.2016.05.010 CrossRefPubMedPubMedCentral

13.

Gandara DR, Li T, Lara PN Jr et al (2014) Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications. Clin Lung Cancer 15(1):1–6. https://doi.org/10.1016/j.cllc.2013.10.001 CrossRefPubMed

14.

Morgan RL, Camidge DR (2018) Reviewing RECIST in the era of prolonged and targeted therapy. J Thorac Oncol 13(2):154–164. https://doi.org/10.1016/j.jtho.2017.10.015 CrossRefPubMed

15.

Castellanos EH, Horn L (2016) Re-Evaluating progression in an era of progress: a review of first- and second-line treatment options in anaplastic lymphoma kinase-positive non-small cell lung cancer. Oncologist 21(6):755–761. https://doi.org/10.1634/theoncologist.2015-0396 CrossRefPubMedPubMedCentral

16.

Mazzeo S, Cervelli R, Elisei R et al (2018) mRECIST criteria to assess recurrent thyroid carcinoma treatment response after radiofrequency ablation: a prospective study. J Endocrinol Invest 41(12):1389–1399. https://doi.org/10.1007/s40618-018-0886-0 CrossRefPubMed

17.

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. https://doi.org/10.1016/j.ejca.2008.10.026 CrossRefPubMed

18.

Oxnard GR, Morris MJ, Hodi FS et al (2012) When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst 104(20):1534–1541. https://doi.org/10.1093/jnci/djs353 CrossRefPubMedPubMedCentral

19.

Wells SA Jr, Asa SL, Dralle H et al (2015) Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25(6):567–610. https://doi.org/10.1089/thy.2014.0335 CrossRefPubMedPubMedCentral

20.

Motzer RJ, Jonasch E, Agarwal N et al (2017) Kidney cancer, Version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 15(6):804–834. https://doi.org/10.6004/jnccn.2017.0100 CrossRef

21.

Park K, Yu CJ, Kim SW et al (2016) First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer: the ASPIRATION Study. JAMA Oncol 2(3):305–312. https://doi.org/10.1001/jamaoncol.2015.4921 CrossRefPubMed

22.

Goto Y, Tanai C, Yoh K et al (2017) Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study. ESMO Open 2(4):e000214. https://doi.org/10.1136/esmoopen-2017-000214 CrossRefPubMedPubMedCentral

23.

Tudor RA, D’Silva A, Tremblay A et al (2017) Beyond disease-progression: clinical outcomes after EGFR-TKIs in a cohort of EGFR mutated NSCLC patients. PLoS One 12(8):e0181867. https://doi.org/10.1371/journal.pone.0181867 CrossRefPubMedPubMedCentral

24.

Hellman S (1994) Karnofsky memorial lecture. Natural history of small breast cancers. J Clin Oncol 12(10):2229–2234CrossRefPubMed

25.

Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13(1):8–10CrossRefPubMed

26.

Weickhardt AJ, Scheier B, Burke JM et al (2012) Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 7(12):1807–1814. https://doi.org/10.1097/jto.0b013e3182745948 CrossRefPubMedPubMedCentral

27.

Triggiani L, Alongi F, Buglione M et al (2017) Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. Br J Cancer 116(12):1520–1525. https://doi.org/10.1038/bjc.2017.103 CrossRefPubMedPubMedCentral

28.

Kelly P, Ma Z, Baidas S et al (2017) Patterns of progression in metastatic estrogen receptor positive breast cancer: an argument for local therapy. Int J Breast Cancer 2017:1367159. https://doi.org/10.1155/2017/1367159 CrossRefPubMedPubMedCentral

29.

Wray J, Hawamdeh RF, Hasija N et al (2017) Stereotactic body radiation therapy for oligoprogression of metastatic disease from gastrointestinal cancers: a novel approach to extend chemotherapy efficacy. Oncol Lett 13(3):1087–1094. https://doi.org/10.3892/ol.2016.5540 CrossRefPubMed

30.

Pacini F, Basolo F, Bellantone R et al (2018) Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies. J Endocrinol Invest 41(7):849–876. https://doi.org/10.1007/s40618-018-0884-2 CrossRefPubMed

31.

Antonelli A, Ferrari SM, Fallahi P (2018) Current and future immunotherapies for thyroid cancer. Expert Rev Anticancer Ther 18(2):149–159. https://doi.org/10.1080/14737140.2018.1417845 CrossRefPubMed

32.

Sherman EJ, Dunn LA, Ho AL et al (2017) Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer. Cancer 123(21):4114–4121. https://doi.org/10.1002/cncr.30861 CrossRefPubMed

33.

Schneider TC, de Wit D, Links TP et al (2015) Beneficial effects of the mtor inhibitor everolimus in patients with advanced medullary thyroid carcinoma: subgroup results of a phase II trial. Int J Endocrinol 2015:348124. https://doi.org/10.1155/2015/348124 CrossRefPubMedPubMedCentral

34.

Rusthoven KE, Kavanagh BD, Burri SH et al (2009) Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 27(10):1579–1584. https://doi.org/10.1200/JCO.2008.19.6386 CrossRefPubMed

35.

Fode MM, Hoyer M (2015) Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases. Radiother Oncol 114(2):155–160. https://doi.org/10.1016/j.radonc.2014.12.003 CrossRefPubMed

36.

Campo M, Al-Halabi H, Khandekar M et al (2016) Integration of stereotactic body radiation therapy with tyrosine kinase inhibitors in stage IV oncogene-driven lung cancer. Oncologist 21(8):964–973. https://doi.org/10.1634/theoncologist.2015-0508 CrossRefPubMedPubMedCentral

37.

Lo SS, Fakiris AJ, Chang EL et al (2010) Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol 7(1):44–54. https://doi.org/10.1038/nrclinonc.2009.188 CrossRefPubMed

38.

de Baere T, Auperin A, Deschamps F et al (2015) Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases. Ann Oncol 26(5):987–991. https://doi.org/10.1093/annonc/mdv037 CrossRefPubMedPubMedCentral

39.

de Baere T, Tselikas L, Woodrum D et al (2015) Evaluating cryoablation of metastatic lung tumors in patients-safety and efficacy: the ECLIPSE trial-interim analysis at 1 year. J Thorac Oncol 10(10):1468–1474. https://doi.org/10.1097/JTO.0000000000000632 CrossRefPubMed

40.

Bhattacharya IS, Hoskin PJ (2015) Stereotactic body radiotherapy for spinal and bone metastases. Clin Oncol (R Coll Radiol) 27(5):298–306. https://doi.org/10.1016/j.clon.2015.01.030 CrossRef

41.

Wang XS, Rhines LD, Shiu AS et al (2012) Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial. Lancet Oncol 13(4):395–402. https://doi.org/10.1016/S1470-2045(11)70384-9 CrossRefPubMedPubMedCentral

42.

Bernstein MB, Chang EL, Amini B et al (2016) Spine stereotactic radiosurgery for patients with metastatic thyroid cancer: secondary analysis of phase I/II trials. Thyroid 26(9):1269–1275. https://doi.org/10.1089/thy.2016.0046 CrossRefPubMed

43.

Cazzato RL, Auloge P, De Marini P et al (2018) Percutaneous image-guided ablation of bone metastases: local tumor control in oligometastatic patients. Int J Hyperthermia 5:1–7. https://doi.org/10.1080/02656736.2018.1508760 CrossRef

44.

Deschamps F, Farouil G, Ternes N et al (2014) Thermal ablation techniques: a curative treatment of bone metastases in selected patients? Eur Radiol 24(8):1971–1980. https://doi.org/10.1007/s00330-014-3202-1 CrossRefPubMed

45.

Covey AM, Sofocleous CT (2008) Radiofrequency ablation as a treatment strategy for liver metastases from breast cancer. Semin Intervent Radiol 25(4):406–412. https://doi.org/10.1055/s-0028-1102996 CrossRefPubMedPubMedCentral

46.

Shady W, Petre EN, Gonen M et al (2016) Percutaneous radiofrequency ablation of colorectal cancer liver metastases: factors affecting outcomes—a 10-year experience at a single center. Radiology 278(2):601–611. https://doi.org/10.1148/radiol.2015142489 CrossRefPubMed

47.

Jackson WC, Tao Y, Mendiratta-Lala M et al (2018) Comparison of stereotactic body radiation therapy and radiofrequency ablation in the treatment of intrahepatic metastases. Int J Radiat Oncol Biol Phys 100(4):950–958. https://doi.org/10.1016/j.ijrobp.2017.12.014 CrossRefPubMed

48.

Paul SB, Sharma H (2014) Role of transcatheter intra-arterial therapies for hepatocellular carcinoma. J Clin Exp Hepatol 4(suppl 3):112–121. https://doi.org/10.1016/j.jceh.2014.03.048 CrossRef

49.

Kudo M, Arizumi T (2017) Transarterial chemoembolization in combination with a molecular targeted agent: lessons learned from negative trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2). Oncology 93(suppl 1):127–134. https://doi.org/10.1159/000481243 CrossRefPubMed

50.

Henriques de Figueiredo B, Godbert Y, Soubeyran I et al (2014) Brain metastases from thyroid carcinoma: a retrospective study of 21 patients. Thyroid 24(2):270–276. https://doi.org/10.1089/thy.2013.0061 CrossRefPubMed

51.

Johung KL, Yeh N, Desai NB et al (2016) Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol 34(2):123–129. https://doi.org/10.1200/JCO.2015.62.0138 CrossRefPubMed

52.

Aoyama H, Shirato H, Tago M et al (2006) Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295(21):2483–2491CrossRefPubMed

53.

Magnuson WJ, Lester-Coll NH, Wu AJ et al (2017) Management of brain metastases in tyrosine kinase inhibitor-naive epidermal growth factor receptor-mutant non-small-cell lung cancer: a retrospective multi-institutional analysis. J Clin Oncol 35(10):1070–1077. https://doi.org/10.1200/JCO.2016.69.7144 CrossRefPubMed

54.

Shukuya T, Takahashi T, Naito T et al (2011) Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure. Lung Cancer 74(3):457–461. https://doi.org/10.1016/j.lungcan.2011.04.007 CrossRefPubMed

55.

Conforti F, Catania C, Toffalorio F et al (2013) EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung. Lung Cancer 81(3):440–444. https://doi.org/10.1016/j.lungcan.2013.05.019 CrossRefPubMed

56.

Takeda M, Okamoto I, Nakagawa K (2013) Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement. J Thorac Oncol 8(5):654–657. https://doi.org/10.1097/JTO.0b013e31828c28e7 CrossRefPubMed

57.

Yu HA, Sima CS, Huang J et al (2013) Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol 8(3):346–351. https://doi.org/10.1097/JTO.0b013e31827e1f83 CrossRefPubMedPubMedCentral

58.

Gan GN, Weickhardt AJ, Scheier B et al (2014) Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. Int J Radiat Oncol Biol Phys 88(4):892–898. https://doi.org/10.1016/j.ijrobp.2013.11.010 CrossRefPubMedPubMedCentral

59.

Hasegawa T, Sawa T, Futamura Y et al (2015) Feasibility of rebiopsy in non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors. Intern Med 54(16):1977–1980. https://doi.org/10.2169/internalmedicine.54.4394 CrossRefPubMed

60.

Yoshida T, Yoh K, Niho S et al (2015) RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation. Lung Cancer 90(3):477–483. https://doi.org/10.1016/j.lungcan.2015.09.025 CrossRefPubMed

61.

Ni Y, Bi J, Ye X et al (2016) Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment: a pilot study. Medicine (Baltimore) 95(25):e3998. https://doi.org/10.1097/MD.0000000000003998 CrossRef

62.

Chan OSH, Lee VHF, Mok TSK et al (2017) The role of radiotherapy in epidermal growth factor receptor mutation-positive patients with oligoprogression: a matched-cohort analysis. Clin Oncol (R Coll Radiol) 29(9):568–575. https://doi.org/10.1016/j.clon.2017.04.035 CrossRef

63.

Qiu B, Liang Y, Li Q et al (2017) Local therapy for oligoprogressive disease in patients with advanced stage non-small-cell lung cancer harboring epidermal growth factor receptor mutation. Clin Lung Cancer 18(6):369–373. https://doi.org/10.1016/j.cllc.2017.04.002 CrossRef

64.

Li X, Qi H, Qing G et al (2018) Microwave ablation with continued EGFR tyrosine kinase inhibitor therapy prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors. Thorac Cancer 9(8):1012–1017. https://doi.org/10.1111/1759-7714.12779 CrossRefPubMedPubMedCentral

65.

Straka C, Kim DW, Timmerman RD et al (2013) Ablation of a site of progression with stereotactic body radiation therapy extends sunitinib treatment from 14 to 22 months. J Clin Oncol 31(23):401–403. https://doi.org/10.1200/JCO.2012.47.7455 CrossRef

66.

Roberto M, Falcone R, Mazzuca F et al (2017) The role of stereotactic body radiation therapy in oligometastatic colorectal cancer: clinical case report of a long-responder patient treated with regorafenib beyond progression. Medicine (Baltimore) 96(48):e9023. https://doi.org/10.1097/MD.0000000000009023 CrossRef

Titel: Local ablative therapy of oligoprogressive TKI-treated thyroid cancer
verfasst von: T. Porcelli
F. Sessa
C. Luongo
D. Salvatore
Publikationsdatum: 01.08.2019
Verlag: Springer International Publishing
Erschienen in: Journal of Endocrinological Investigation / Ausgabe 8/2019
Elektronische ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-019-1001-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Local ablative therapy of oligoprogressive TKI-treated thyroid cancer

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2019

Next-generation sequencing identifies novel mitochondrial variants in pituitary adenomas

Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model

Hypothalamic–pituitary–adrenal axis function in traumatic spinal cord injury-related neuropathic pain: a case–control study

Thyroid hormone resistance from newborns to adults: a Spanish experience

The clinical enigma of the “Flea catcher” by Georges de La Tour: a pregnant sinner with pre-eclampsia or a hypothyroid girl?

Bilateral inferior petrosal sinus sampling in adrenocorticotropin-dependent hypercortisolism: always, never, or sometimes?

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin